Table 5 Target Family Performance Comparison
From: Industry-scale application and evaluation of deep learning for drug target prediction
ExCAPE-ML | AstraZeneca | Janssen | ||||
|---|---|---|---|---|---|---|
Target family | Targets w./sz. | p-value | Target w./sz. | p-value | Targets w./sz. | p-value |
Oxidoreductase | 25/37 | 2.17e−05 | 7/18 | 3.91e−01 | 16/32 | 3.77e−02 |
Transferase | 141/158 | 1.58e−48 | 77/143 | 3.64e−07 | 60/153 | 7.38e−02 |
Hydrolase | 63/92 | 6.24e−12 | 21/47 | 6.96e−02 | 36/77 | 9.91e−03 |
Lyase | 4/8 | 2.59e−01 | 0/0 | 4/8 | 2.59e−01 | |
Isomerase | 4/6 | 1.00e−01 | 0/1 | 1.00e + 00 | 4/6 | 1.00e−01 |
GPCR Fam. A | 76/94 | 3.78e−21 | 34/70 | 5.87e−03 | 66/93 | 1.39e−13 |
GPCR Fam. B | 3/5 | 2.10e−01 | 0/5 | 1.00e + 00 | 2/5 | 5.39e-01 |
GPCR Fam. C | 3/5 | 2.10e−01 | 1/5 | 8.68e-01 | 5/5 | 4.12e-03 |
Nuclear Hormone Receptor | 14/20 | 8.79e−04 | 9/17 | 7.55e−02 | 13/19 | 1.87e−03 |
Reader | 2/7 | 7.37e−01 | 1/1 | 3.33e−01 | 2/2 | 1.11e−01 |
Eraser | 7/9 | 8.28e−03 | 5/7 | 4.53e-02 | 4/7 | 1.73e-01 |
Writer | 3/3 | 3.70e−02 | 1/1 | 3.33e−01 | 0/1 | 1.00e + 00 |
Ligand-gated | 3/6 | 3.20e−01 | 1/4 | 8.02e−01 | 2/6 | 6.49e−01 |
Voltage-gated | 6/12 | 1.78e−01 | 3/9 | 6.23e−01 | 6/12 | 1.78e−01 |
Primary active | 3/4 | 1.11e−01 | 0/2 | 1.00e + 00 | 2/4 | 4.07e−01 |
Electrochem. | 7/10 | 1.97e−02 | 2/8 | 8.05e−01 | 3/8 | 5.32e−01 |
Overall | 364/476 | 1.26e−82 | 162/338 | 2.02e−08 | 225/438 | 5.95e−15 |